目的 研究达比加群酯与华法林对非瓣膜性心房颤动(NVAF)患者的临床疗效和安全性.方法 选择2016年1月至2017年12月接受治疗的NVAF患者88例.用随机数表法分为对照组和观察组,每组各44例.对照组给予华法林治疗,观察组给予达比加群酯治疗.比较两组患者的凝血指标、出血事件、栓塞事件和不良反应的发生率.结果 治疗后两组患者的部分活化凝血酶原时间(APTT)、凝血酶时间(TT)、凝血酶原时间(PT)和国际标准化比值(INR)水平均明显升高,观察组患者上述指标高于对照组(P0.05).观察组患者出血事件的发生率为4.55%,栓塞事件的发生率为9.09%,而对照组患者出血事件的发生率为20.45%,栓塞事件的发生率为27.27%(P0.05).结论 达比加群酯治疗NVAF的临床疗效优于华法林,凝血指标改善更佳,出血事件和栓塞事件的发生率较低,且无需频繁抽血监测凝血功能,其优势更加明显,值得在临床推广应用.%Objective To study the clinical efficacy and safety of dabigatran etexilate and warfarin in patients with non valvular atrial fibrillation (NVAF). Methods 88 patients with NVAF in our hospital were selected from January 2016 to December 2017. The patients were randomly divided into control group and observation group,44 cases in each group. The control group was treated with warfarin,the observation group was treated with dabigatran etexilate. The coagulation indexes,bleeding events,embolic events and incidence of adverse reactions were compared between the two groups. Results After treatment,the levels of APTT,TT,PT and INR in the two groups were significantly higher than those in the control group (P0.05). The incidence of bleeding events in the observation group was 4.55%,the incidence of embolic events was 9.09%,while the incidence of bleeding events in the control group was 20.45%,and the incidence of embolic events was 27.27%(P0.05). Conclusion Dabigatran etexilate is better than warfarin in the treatment of NVAF,the improvement of coagulation index is better,the incidence of bleeding events and embolic events is lower,and there is no need for frequent blood sampling to monitor the blood coagulation function. It has more obvious advantages,and it is worth popularizing in clinical application.
展开▼
